These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 10467820)

  • 21. Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance.
    Greeson NM; Mixon W; Allan WC
    Int J Pharm Compd; 2020; 24(5):371-379. PubMed ID: 32886634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proposed rule: current good manufacturing practice in manufacturing, packing, or holding dietary ingredients and dietary supplements.
    Melethil S
    Life Sci; 2006 Mar; 78(18):2049-53. PubMed ID: 16516243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The "Negative" List.
    Allen LV
    Int J Pharm Compd; 2015; 19(4):311-3. PubMed ID: 26625568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Judge allows bulk ingredients for compounding: ruling favors pharmacy, but FDA can still distinguish manufacturing, compounding.
    Cima G
    J Am Vet Med Assoc; 2011 Nov; 239(10):1266-68. PubMed ID: 22044321
    [No Abstract]   [Full Text] [Related]  

  • 25. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
    Yoch D
    Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sterile compounding: clinical, legal, and regulatory implications for patient safety.
    Qureshi N; Wesolowicz L; Stievater T; Lin AT
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1183-91. PubMed ID: 25443512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Dietary Supplement and Health Education Act and supplements: dietary and nutritional supplements need no more regulations.
    Wollschlaeger B
    Int J Toxicol; 2003; 22(5):387-90. PubMed ID: 14555412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of botanicals in food supplements. Regulatory scope, scientific risk assessment and claim substantiation. 2005.
    Coppens P; Delmulle L; Gulati O; Richardson D; Ruthsatz M; Sievers H; Sidani S;
    Ann Nutr Metab; 2006; 50(6):538-54. PubMed ID: 17191027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA, states discuss pharmacy compounding regulatory framework.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(3):180, 182. PubMed ID: 23327976
    [No Abstract]   [Full Text] [Related]  

  • 30. The history of efforts to regulate dietary supplements in the USA.
    Swann JP
    Drug Test Anal; 2016; 8(3-4):271-82. PubMed ID: 26593452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Food and drug regulatory issues.
    Stribling J; Picut C
    Vet Clin North Am Small Anim Pract; 1993 Sep; 23(5):991-1005. PubMed ID: 8236626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The importance of using scientific principles in the development of medicinal agents from plants.
    Talalay P; Talalay P
    Acad Med; 2001 Mar; 76(3):238-47. PubMed ID: 11242573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective.
    Collins N; Tighe AP; Brunton SA; Kris-Etherton PM
    J Am Coll Nutr; 2008 Dec; 27(6):659-66. PubMed ID: 19155425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is in the can? The dilemma with dietary supplements.
    D'Aco K; Mooney R; Cusmano-Ozog K; Hofherr S; Lichter-Konecki U
    Mol Genet Metab; 2014 Dec; 113(4):239-40. PubMed ID: 25453401
    [No Abstract]   [Full Text] [Related]  

  • 36. Medical Device; exemption from premarket notification; class II devices; pharmacy compounding systems. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Mar; 66(55):15796-8. PubMed ID: 11706859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional foods: the Food and Drug Administration perspective.
    Ross S
    Am J Clin Nutr; 2000 Jun; 71(6 Suppl):1735S-8S; discussion 1739S-42S. PubMed ID: 10837331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Developments in food and drug law.
    Masoudi GF
    Food Drug Law J; 2005; 60(2):107-16. PubMed ID: 16097088
    [No Abstract]   [Full Text] [Related]  

  • 39. President signs compounding law.
    Traynor K
    Am J Health Syst Pharm; 2014 Jan; 71(1):7. PubMed ID: 24352171
    [No Abstract]   [Full Text] [Related]  

  • 40. Herbal supplements and prescription drugs. A risky combination?
    Stein K
    J Am Diet Assoc; 2000 Apr; 100(4):412. PubMed ID: 10767891
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.